Floatz logo

cll1-cd33 ccar t cells

Chronic Myeloid Leukemia

iCell Gene TherapeuticsCell therapyEarly Phase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
81/ 100

Competitive context

86 Active assets in the Chronic Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BBB
Therapeutic Allogeneic Lymphocytes
University of Chicago
Phase 2BBB
Romidepsin
Center for International Blood and Marrow Transplant Research
Phase 2BBB

View all 50 →

Same molecule, other indications

cll1-cd33 ccar t cells is also rated in:

acute myeloid leukemiaDormant
CC
Indicative ·
41 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
41 / 100
View asset →
myeloproliferative neoplasmDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →